3Zhang Y, Yu LK, Lu GJ, et al. Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer[ ] ]. Asian Pac J Cancer Prey, 2014 ; 15 (19) :8435 - 40. 被引量：1
4Zhou WB, Bal M, Jin Y. Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions[ J]. Int J Tubere Lung Dis. 2009,13(3) :381 -386. 被引量：1
5Pichelmayer O, Gruenberger B, Zielinski C, et al. Bevacizumab is active in malignant effusion [J]. Ann Oncol, 2006, 17(12) : 1853. 被引量：1
6Venneri MA, De Palma M, Ponzoni M, et al. Identification of proangiogenic TIE2-expressing monoeytes (TEMs) in human pe- ripheral blood and cancer [ J ]. Blood, 2007,109 ( 12 ) : 5276 - 5285. 被引量：1
7Tomimoto H, Yano S, Mugnruma H, et al. Levels of soluble vascular endothelial growth factor receptor 1 are elevated in the exudative pleural effusions[J]. J Med Invest,2007,54(1-2) :146- 153. 被引量：1
8Kalomenidis I, Kollintza A, Sigala I, et al. Angiopoietin-2 levels are elevated in exudative pleural effusions [ J ]. Chest, 2006 ; 129 (5) :1259-66. 被引量：1
9Hashizume H, Falc6n BL, Kuroda T, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth[J]. Cancer Res,2010,70(6) :2213 -2223. 被引量：1
10Koh YJ, Kim HZ, Hwang St, et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage [ J ]. Cancer Cell, 2010,18 ( 2 ) : 171 - 184. 被引量：1
